EdiGene Secures Over RMB 10 Million in Angel Funding to Accelerate Industrial Application of Gene Editing Technologies

VCBeat has learned at the earliest opportunity that recently,Guangzhou Aidi Gene Technology Co., Ltd. (hereinafter referred to as: Aidi Gene), announced the completion ofYanghe Investment, Zhongda Venture Capital, GreatWallFundCo-investmentAngel Round Financing Exceeding RMB 10 Million. The funds raised in this round will be used to accelerate the company's team building, enhance its R&D capabilities, optimize product portfolio, and expand into overseas markets.

This financing round marks the capital market’s recognition of the team and entrepreneurial vision at Guangzhou Aidi Gene Technology Co., Ltd. It will significantly enhance the company’s service capabilities in the field of gene editing technology, enabling it to respond more rapidly and efficiently to market demands and provide customized solutions for enterprises seeking gene editing technologies.

Guangzhou Aidi Gene Technology Co., Ltd. was established in August 2017 and is located at the International Business Incubator in Huangpu District, Guangzhou. The company was founded by a returning Ph.D. holder with ten years of dedicated expertise in gene editing technology, having accumulated extensive industry experience in CRISPR/Cas gene editing.

After years of technological research and development, Aidi Gene has established four core technology platforms by conducting foundational R&D based on CRISPR/Cas technology, keeping pace with advanced international technologies, and adhering to technological innovation:Editx™ gene editing, Bingo™ point mutation, LION™ site-specific cell insertion, and FASST rapid nucleic acid detection,Providing More Comprehensive Technical Services for the Ever-Evolving Gene Editing Research.

Aidi Gene is committed to foundational technology R&D, engineeringing gene-editing enzymes based on three-dimensional structural analysis. Through its independently developed preparation processes, the company has produced enzyme formulations that significantly outperform those of well-known international competitors, earning widespread customer recognition. Its gene knockout kits, developed using novel transfection reagents, enable rapid and scarless gene knockout in cells with no cytotoxicity, achieving an editing efficiency of up to 95% in cell lines such as THP-1.; launched the Bingo™ point mutation platform, which is deeply optimized based on PE technology. The technical team has completed experiments in various hard-to-transfect cell lines, achieving an editing efficiency of up to 85%; the FASST rapid nucleic acid detection platform, developed based on the CRISPR system, enables single-tube reactions with a detection time of 20 minutes and a sensitivity of 10 copies.

Aidi Gene has cultivated the domestic market in depth, providing CRO services to numerous research institutions and enterprises in China, thereby establishing a solid market foundation.

Today, Aidi Gene is advancing onto the international stage with greater resolve. Leveraging the proven success and robust quality of its domestic products, the overseas team has successfully establishedWestern Europe, East Asia, North Americasales channels in overseas countries and regions. Looking ahead, Aidi Gene is committed to building the largest and most comprehensive gene editing service platform, offering end-to-end services related to gene editing,As a “Catalyst” for the Gene Editing Industry, accelerating the industrialization of gene editing to benefit human health.

Dr. Gai Zuoqi, Co-founder of Aidi Genestated, “During this special period, we are deeply honored to have gained the favor and support of investment institutions. This is not only an affirmation of the past efforts of the Guangzhou Aidi Gene Technology Co., Ltd. team, but also an expectation for our future development.”We will seize this opportunity to deepen our understanding of customer needs, continuously increase investment in technological innovation, and accelerate the process of cell and gene editing. Our goal is to make gene editing accessible to novices, enhance its application for practitioners, and reduce costs for experts, thereby allowing gene editing technology to truly shine.”

Dr. Zhang Xu, Co-founder and Chief Technology Officer of Aidi GeneHe stated, “We appreciate the investors’ recognition of the Aidi team, our corporate philosophy, and our technology platform. Over the past few years, our team has continuously pursued application-driven innovations in the field of gene editing, establishing a leading CRISPR/Cas-based technology service platform in China that offers knockout, point mutation, targeted insertion, and rapid nucleic acid detection services. Our product portfolio is also being continually refined; high-quality enzymes for gene editing and efficient delivery systems for knockout RNPs, among other products, are already serving upstream and downstream sectors of the gene editing industry. With the support from this round of financing, we believe Aidi Gene will leverage its technologically superior services and products to fuel the rapid development of the domestic and international gene editing industries over the next one to two years.”

Yanghe Investmentstated: “Yanghe Investment has been dedicated to early- and mid-stage investments in the fields of medical devices and biotechnology, with strategic presence in life science research tools and services. Gene editing technology is at the forefront of life sciences, poised to significantly transform research methodologies and application directions in the field, holding immense potential for development. The team at Guangzhou Aidi Gene Technology Co., Ltd. has deeply cultivated the gene editing sector, committing to innovation and promotion of gene editing technologies, backed by extensive experience in R&D and customer service. We believe that Aidi Gene will create greater value in the field of gene editing.”

Zhongda Venture Capitalstated: “We are highly optimistic about the future prospects of CRISPR gene-editing technology, which is seeing increasingly broad applications in cell and gene therapy, as well as across the entire biotechnology sector. Guangzhou Aidi Gene Technology Co., Ltd. was founded by two overseas-returned PhDs with extensive experience in the field of CRISPR gene editing. Grounded in independent R&D and committed to continuous breakthroughs, the company has achieved a series of outstanding technical results and gained recognition from a number of clients both domestically and internationally. This investment not only affirms Aidi Gene’s capabilities and achievements but also reflects our firm belief in the long-term value of the biotechnology sector. Zhongda Venture Capital looks forward to partnering with the Aidi Gene team, leveraging complementary strengths to jointly advance the industrialization of CRISPR gene-editing technology.”

GreatWallFund Healthcare and Biotech Investment Teamstated: “We deeply recognize the future development potential of CRISPR technology. Guangzhou Aidi Gene Technology Co., Ltd. has been deeply engaged in gene editing for many years and possesses a distinctive R&D platform for gene editing. It was the first in China to employ prime editing-based point mutation services for constructing genetic disease models, earning customer recognition in the construction of complex cell lines with multiple gene point mutations. In the arena of CRISPR gene editing technology, it is globally competitive. We have always been committed to identifying and investing in biotech companies with innovative potential and market prospects. We believe that through this investment, we will join hands with Guangzhou Aidi Gene Technology Co., Ltd. to usher in a new chapter in gene editing technology.”

Founded in 2013, Yanghe Investment is a China-based industrial investment firm specializing in niche sectors of the healthcare industry. It focuses primarily on medical technologies, innovative medical devices, and healthcare services, with its portfolio concentrated in early- to mid-stage companies. Adhering to a long-term strategy of uncovering investment opportunities through in-depth research of niche markets, the firm empowers its portfolio companies and achieves its own growth by fostering the development of its investments. To date, Yanghe Investment has invested in more than 30 high-quality enterprises, including Vishee Medical, Libo Pharmaceutical, Kanglu Biotechnology, Mingkang Medical, Genewell Biotechnology, Respree, Ruitong Biopharma, and Bosheng Medical.

Zhongda Venture Capital, established in 2011, is an emerging industry investment institution dedicated to leveraging the advantages and resources of Chinese universities in technological innovation, industrial research, and talent development. It mobilizes and allocates social capital to support the commercialization of scientific and technological achievements, with a focus on equity investment, fund management, IPOs, and mergers and acquisitions.

Zhongda Venture Capital adheres to the investment philosophy of “trend-based investing, industry-focused investing, ecosystem building, and aggregated innovation.” It focuses on investing in three emerging industrial sectors: biopharmaceuticals, new materials, and advanced manufacturing. Its portfolio of outstanding companies includes Maiqi Chemical, Jiajian Medical, Sianxin Biotechnology, Baisheng Biotechnology, Zhongke Ruiji, Ruitai Biotechnology, and Weichun Biotechnology.

Through years of exploration and development, Zhongda Venture Capital has established a development model centered on “industrial clusters + industrial capital + innovation ecosystem.” By strategically laying out three major industrial clusters—Guangdong Medical Valley, Guangdong Materials Valley, and Zhongda Innovation Valley—it has built unique advantages in fields such as biopharmaceuticals, new materials, and advanced manufacturing. The company continuously facilitates industrial innovation and the commercialization of scientific and technological achievements, while investing in and incubating innovative enterprises with high growth potential.

Qianhai Great Wall Fund, officially known as Qianhai Great Wall Fund Management (Shenzhen) Co., Ltd. (GreatWallFund), is a professional investment institution specializing in strategic emerging industries such as biomedicine, semiconductors, new energy, and new materials. Upholding long-termism as the cornerstone of value investing, it practices a distinctive value investment philosophy and adheres to an investment logic characterized by “broad tracks, full-chain coverage, selection of industry leaders, and people-centric approach.” The firm focuses on an investment strategy of “investing early, investing in small enterprises, investing in innovation, investing in hard technology, investing in domestic substitution, and investing in specialized fields,” striving to become a hidden champion among “specialized, refined, distinctive, and innovative” enterprises in the venture capital sector.